European Parliament Lead on Clinical Trials Regulation gets tough on transparency
This article was originally published in Scrip
The lead legislator on the proposed Clinical Trials Regulation at the European Parliament has called for major transparency-related changes to be made to the draft legislation. Glenis Willmott has suggested, among other things, that the proposed text of the CTR be amended to clarify that "clinical trial data should not be considered commercially confidential once a marketing authorization has been obtained [by a drug company]".
You may also be interested in...
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Twenty-four guidance documents have been posted on the tracker since its last update.
The risk of psychiatric disorders with chloroquine and hydroxychloroquine-containing medicines received renewed attention in the EU after they were being used as potential treatments for COVID-19.
New UK guidance explains how clinical trial sponsors and investigator sites can ensure that trial monitors securely process data in electronic health record systems that do not have a restricted access functionality.